Europe Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care), And By Geography - Forecasts From 2023 To 2028

The Europe CGM market is expected to grow at a CAGR of 19.46%, from an initial value of US$1,033.055 million in 2021 to US$3,586.408 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint all because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

The market for continuous glucose monitoring systems in Europe is anticipated to experience substantial development due to several benefits of CGMS, such as low invasiveness and real-time blood glucose monitoring. The expansion of the EU CGMS market is also anticipated to be fueled by a rise in healthcare spending per person, an increase in the prevalence of diabetes in Europe, and an increase in purchasing power brought on by high disposable income. Its expansion is complemented by the fact that CGMS offers more accurate blood glucose analysis and better accuracy than conventional blood glucose monitoring. The European market for continuous glucose monitoring systems and the global market for CGMS are both constrained by high costs associated with CGMS, inadequate reimbursement schemes, and severe regulatory restrictions.

CGM sensors hold the maximum share of continuous glucose monitoring in the European market.

The essential part of CGM equipment is its sensors. Growth in the category is anticipated to be fueled by technical developments that increase sensor accuracy throughout the projected period. Continuous glucose monitoring has grown in popularity as a portable finger-prick glucometer substitute for diabetic patients. Additionally, modern continuous glucose monitoring systems may either download data to illustrate trends in blood glucose levels or use receiver displays to show glucose levels in real-time.

Technological advancements in continuous glucose monitoring influence the market.

When compared to the typical routine of testing blood glucose levels at predetermined intervals, CGMs provide a more detailed view of blood glucose patterns and trends. The current CGM systems may either download data to retroactively depict patterns in blood glucose levels or provide receiver displays with real-time glucose readings. To help with prompt blood glucose control, the majority of real-time CGMs may provide alerts to patients, parents, or carers during present or upcoming glycemic encounters. The CGM market is anticipated to have stable expansion throughout the forecast period due to this aspect as well as the fact that CGM devices are becoming more affordable with the introduction of new technologies, such as mobile phone integration.

Germany is projected to be the prominent market shareholder in the CGM Market in Europe and is anticipated to continue throughout the forecast period.

One of the highest diabetes prevalence rates in the continent of Europe is found in Germany. In-depth scientific research is carried out by the German Center for Diabetes Research (DZD) to create efficient preventative and therapeutic strategies to slow the development or progression of diabetes. Insulin pumps must be used in conjunction with CGM devices. It has been noted that there may be a possible rise in the number of people with diabetes, which may be directly linked to an increase in the proportion of diabetic patients using insulin pumps. As a result, it is anticipated that sales of CGM devices would increase. Consequently, it is projected that the studied market will develop in Germany as a result of the aforementioned reasons.

Market Key Developments

• In June 2022, Senseonics Holdings, Inc., a partner of Ascensia Diabetes Care, received CE Mark approval for the Eversense E3 Continuous Glucose Monitoring (CGM) System, paving the way for its use in European Union (EU) member countries. Ascensia Diabetes Care is the manufacturer of the Contour blood glucose monitoring (BGM) system portfolio and distributor of Eversense Continuous Glucose Monitoring (CGM) Systems.
• In March 2022, With a CE Mark (Conformité Européenne), the Dexcom G7 continuous glucose monitoring (CGM) system is authorized for use in Europeans with diabetes who are 2 years of age and older, including pregnant women.

Europe Continuous Glucose Monitoring (CGM) Market Scope:

Segmentation:

• By Application
  • Diabetes Patients
  • Critical Patients
• By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care
• By Geography
  • Germany
  • Spain
  • France
  • UK
  • Others